Explore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.
We work closely with the 27 EU Member States plus Norway and Türkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.
We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon.
GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery Kelly Clarkson Fake
Location
Lisbon
Publication date
Reference
News release
In United States Publish Post Time: 2025-08-22
GLP-1 receptor agonists have become a sensation in the world of obesity and metabolism, sparking debates and making headlines. Are they the miracle solution for weight loss, or is there more to the story? In this video, I’ll break down the science behind GLP-1 medications and explore their effects beyond the scale.
Chapters
0:00 – What if GLP-1 Aren’t Just Weight Loss Drugs?
1:10 – Upfront Caveat and Framing
2:08 – New Review on GLP-1, Beyond Weight Loss
2:41 – Research on GLP-1, the Brain, and Inflammation
4:23 – Summary on these Data
4:39 – Relationship to Human Data
5:49 – The Core Truth
7:01 – Even Better than GLP-1…
References can be found in associated newsletter:
#glp1 #weightloss #inflammation #neuroscience #metabolichealth #metabolism #staycurious
GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery For Country: United States. City: Fairfield, Indianapolis, Pittsburgh, Syracuse, Zion
To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:
Kathy Robertson
Principal manager
Media relations and corporate communication